Clinical Trial Update: A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with docetaxel and capecitabine as first-line treatment for locally recurrent and metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Locally Recurrent and Metastatic Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED